

# ARV-393-101


# ARV-393

## NOW ENROLLING

### A Phase 1 First-in-Human Study of ARV-393 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

ARV-393 is an investigational compound and is not approved for any use. Its safety and effectiveness have not been established.

#### Trial Schema



This information is current as of November 2024.



For additional protocol details, please visit [www.ClinicalTrials.gov\(NCT06393738\)](http://www.ClinicalTrials.gov(NCT06393738))

## Key Eligibility Criteria<sup>a</sup>

### Inclusion Criteria

- Men and women aged  $\geq 18$  years
- Relapsed/refractory mature B-cell NHL or histologically confirmed nTFHL-AI that has recurred or progressed
  - $\geq 2$  lines of prior therapy for patients with relapsed/refractory mature B-cell NHL
  - Progression or disease recurrence following standard of care therapy for patients with nTFHL-AI
- $\geq 1$  measurable lesion at study entry
- ECOG performance status of 0 or 1
- Freshly biopsied or archival tumor tissue available

### Exclusion Criteria

- Prior allogeneic stem cell transplant
- Significant acute or chronic medical illness, including hypereosinophilic syndrome, active interstitial lung disease or pneumonitis, or active or uncontrolled infection

## Summary of Outcome Measures

### Primary Endpoints

- DLTs
- Safety and tolerability

### Secondary Endpoints

- Pharmacokinetic parameters of ARV-393
- ORR,<sup>b</sup> CRR,<sup>c</sup> and DOR

<sup>a</sup>This is not the complete list of inclusion/exclusion criteria.

<sup>b</sup>The proportion of participants achieving a complete response or partial response according to the Lugano response criteria for NHL.

<sup>c</sup>The proportion of participants achieving a complete response according to the Lugano response criteria for NHL.

AE=adverse event; AITL=angioimmunoblastic T-cell lymphoma; CRR=complete response rate; DLT=dose-limiting toxicity; DOR=duration of response; ECOG=Eastern Cooperative Oncology Group; NHL=non-Hodgkin lymphoma; nTFHL-AI=nodal T-follicular helper cell lymphoma, angioimmunoblastic-type; ORR=objective response rate.